Subsequent Event (Details)	Jul. 03, 2017
Subsequent Event \| Novartis Pharma AG \| Licensing and Commercialization Agreement
Subsequent Event [Line Items]
Percent of cost and expense of clinical trials each party will be required to fund if unable to agree on funding	50.00%

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

No definition available.

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration